Story perspectives

FDA Approves Bristol Myers Squibb’s Zenbexus for Myeloma

8/15/2026

Summary

Story summary

The U.S. FDA granted approval on 13 August 2026 to Bristol Myers Squibb’s Zenbexus (iberdomide), the first cereblon-modulating (CELMoD) degrader for myeloma patients with prior therapy.
In the EXCALIBER-RRMM trial, 41% of Zenbexus patients achieved MRD-negative response versus 21% with comparator, while 7.8% discontinued and 4.9% died, mainly from sepsis.
Bristol Myers Squibb priced Zenbexus at $29,500 per 28-day cycle, with analyst Matt Phipps expecting sales above $1 billion by 2031.

1 of 1

Story summary

The U.S. FDA granted approval on 13 August 2026 to Bristol Myers Squibb’s Zenbexus (iberdomide), the first cereblon-modulating (CELMoD) degrader for myeloma patients with prior therapy.
In the EXCALIBER-RRMM trial, 41% of Zenbexus patients achieved MRD-negative response versus 21% with comparator, while 7.8% discontinued and 4.9% died, mainly from sepsis.
Bristol Myers Squibb priced Zenbexus at $29,500 per 28-day cycle, with analyst Matt Phipps expecting sales above $1 billion by 2031.